Recombinant vectors based on a non-pathogenic human parvovirus, the adeno-associated virus 2 (AAV2) have been developed, and are currently in use in a number of gene therapy clinical trials. More recently, a number of additional AAV serotypes have also been isolated, which have been shown to exhibit selective tissue-tropism in various small and large animal models 1 . Of the 10 most commonly used AAV serotypes, AAV3 is by far the least efficient in transducing cells and tissues in vitro as well as in vivo.
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However, in our recently published studies, we have documented that AAV3 vectors transduce human liver cancer -hepatoblastoma (HB) and hepatocellular carcinoma (HCC) -cell lines extremely efficiently because AAV3 utilizes human hepatocyte growth factor receptor as a cellular coreceptor for binding and entry in these cells 2, 3 .
In this article, we describe the steps required to achieve high-efficiency transduction of human liver cancer cells by recombinant AAV3 vectors carrying a reporter gene. The use of recombinant AAV3 vectors carrying a therapeutic gene may eventually lead to the potential gene therapy of liver cancers in humans.
Video Link
The 6. Remove medium after 4 hours, replacing with fresh 25 mL complete medium+10%FBS (C-DMEM). 7. Seventy two hours post-transfection, scrape cells and pour into a 250 mL conical centrifuge tube. 8. Spin at 3000 rpm, at 4°C for 10 min. Pour off supernatant. 9. Re-suspend the cell pellet in 5 mL of RB TMS Buffer (50 mM Tris-HCl, 150 mM NaCl, pH 8.0). Transfer to a new 15 mL conical tube. 10. Freeze in dry ice-ethanol bath for 10 min and thaw at 37°C for 10 min. Repeat three times. 11. Add 1 μL of 4.8 M MgCl 2 and 2 μL of Benzonase (25 U/ μL, Novagen, Cat# 70664-3). Vortex and incubate in 37°C for 40 min. 12. Spin down at 4,000 rpm, at 4°C for 40 min and collect the supernatant (clarified lysate). 13. In a 13 mL Quick-Seal centrifuge tube (Beckman, Cat# 342413), load iodixanol gradient (OptiPrep, Cat# 1114542) from top to bottom: 2 mL of 15%, 2 mL of 25%, 1.5 mL of 40% and 1.5 mL of 60% iodixanol. Load the supernatant (Step 1.12) on the top of iodixanol gradient. Fill the tubes with RB TMS Buffer. 14. Centrifuge at 75,000 rpm for 1 hour at 16°C using Beckman 90Ti rotor. 15. Collect the 40% iodixanol fraction by inserting a syringe at 40-60% boundary. 16 . Transfer the 40% iodixanol fraction in one 50 mL conical tube and make up to 40 mL with Buffer A (20 mM Tris, 15 mM NaCl, pH 8. 
Discussion
Recombinant vectors based on a non-pathogenic human parvovirus, the adeno-associated virus (AAV) have been developed, and are currently in use in a number of gene therapy clinical trials 5 . Previously, of the 10 most commonly used AAV serotypes, the transduction efficiency of AAV3 vectors in general has been reported to be particularly low, both in vitro and in vivo 1 . However, our recent observation that AAV3 vectors transduce human liver cancer cell lines exceedingly well, as determined quantitatively by flow cytometry 2 , and that AAV3 utilizes the human hepatocyte growth factor receptor (hHGFR) as a cellular co-receptor for binding and entry in these cells 3 , strongly suggest a selective tissuetropism of AAV3 for human liver cells in general, and human liver cancer cells in particular. However, since AAV3 vectors also transduce normal human hepatocytes efficiently 2 , their potential use in cancer gene therapy application in vivo would be negatively impacted. One possible strategy to circumvent this potential problem involves transcriptional-targeting of cancer cells by identifying a gene product that is selectively produced by the tumor, but not by normal hepatocytes. For example, previous studies have shown that serum levels of α-fetoprotein (AFP) are used as a specific marker for tracking the presence, progression, and/or reoccurrence of certain types of liver cancers, since normal hepatocytes generally produce very small amounts of this protein. Indeed, we have used AAV3 vectors containing the AFP promoter to target transgene expression in liver cancer cells, but not in normal hepatocytes 2 , and studies are currently underway to test the efficacy of this approach in a murine xenograft model of liver cancer. In our additional studies, we have observed that the transduction efficiency of various AAV serotype vectors can be significantly augmented by site-directed mutagenesis of surface-exposed tyrosine residues in the viral capsids [6] [7] [8] [9] [10] [11] [12] [13] [14] . Since 6 of 7 surface-exposed tyrosines are also conserved in AAV3, we have performed site-directed mutagenesis of these residues and observed that the transduction efficiency of tyrosine-mutant AAV3 vectors is significantly enhanced in human liver cancer cells (unpublished data). Studies are also currently underway to evaluate the safety and efficacy of the tyrosine-mutant AAV3 vectors in mouse xenograft models for human hepatoblastoma and hepatocellular carcinoma, and if successful, the optimal tyrosine-mutant AAV3 serotype vectors may prove to be useful for targeting human liver cancers for the potential gene therapy.
